Once spurned, Amgen wins the FDA over with its bone-building osteoporosis drug Evenity
As expected, Amgen’s once-rejected osteoporosis drug has scored FDA approval, paving the way for a new bone-building option for the one in two postmenopausal women …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
